James Paul Rickey
Chief Financial OfficerMr. James Paul Rickey serves as Chief Financial Officer of Braveheart Bio, Inc. since November 2025. He had been Senior Vice President and Chief Financial Officer of Alpine Immune Sciences Inc. since April 2017 and had been its Treasurer since December 2018 and Secretary since March 2019. Mr. Rickey is an experienced executive who has guiding financial strategy in the life sciences and technology industries. Mr. Rickey served as the Chief Financial Officer, Senior Vice President and Secretary at Nivalis Therapeutics, Inc. since July 24, 2017. He served as the Chief Financial Officer of Sound Pharmaceuticals, Inc. from March 1, 2016 to April 6, 2017. Mr. Rickey served as Vice President of Finance and Administration of Immune Design Corp., where he helped complete its private offerings, initial public offering and follow-on financing. In addition, he oversaw the finance, accounting and human resource functions through July 2015. Before joining Immune Design in 2009, he was Corporate Controller of Northstar Neuroscience, a publicly traded medical device company, where he managed its finance and accounting groups following their IPO. Prior to his role at Northstar Neuroscience, he served as an Accounting Manager for Mobliss, Inc. He started his career at Ernst & Young LLP in 2001. Mr. Rickey graduated from the University of Washington with a BA and Masters in Professional Accounting and is a Certified Public Accountant (inactive).
Positions
- Company NameBraveheart Bio, Inc.Stock CodeBRVEPositionChief Financial OfficerColleagues
- TMTravis MurdochCEO, President & Director
- CAChristopher A. ViehbacherIndependent Chairman
- MAMichele A. AndersonChief Development Officer
- MEMarc EvanchikChief Scientific Officer
- NDNatalie DementVP & Head of Legal
- JMJasper M. BosIndependent Director
- DCDavid Charles LubnerIndependent Director
- ECErez ChimovitsIndependent Director
